126 related articles for article (PubMed ID: 2768892)
1. Preoperative and longitudinal serum levels of CA 125 and CA 15.3 in patients with breast cancer.
Omar YT; Behbehani AE; al-Naqeeb N; Motawy MM; Foudeh MO; Awwad AH; Nasralla MY; Szymendera JJ
Int J Biol Markers; 1989; 4(2):81-6. PubMed ID: 2768892
[TBL] [Abstract][Full Text] [Related]
2. Value of serum levels of carcinoembryonic antigen, CEA, and gastrointestinal cancer antigen, GICA or CA 19-9, for preoperative staging and postoperative monitoring of patients with colorectal carcinoma.
Szymendera JJ; Nowacki MP; Kozłowicz-Gudzińska I; Kowalska M
Dis Colon Rectum; 1985 Dec; 28(12):895-9. PubMed ID: 3864628
[TBL] [Abstract][Full Text] [Related]
3. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
[TBL] [Abstract][Full Text] [Related]
4. Carcinoembryonic antigen and breast carcinoma antigen (CA 15.3) in preoperative staging and postoperative monitoring of patients with carcinoma of the breast.
Omar YT; Behbehani AE; al-Naqeeb N; Motawy MM; Folldi MO; Awwad AH; Nasralla MY; Szymendera JJ
Int J Biol Markers; 1988; 3(3):165-71. PubMed ID: 3230336
[TBL] [Abstract][Full Text] [Related]
5. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases.
Colomer R; Ruibal A; Genollá J; Rubio D; Del Campo JM; Bodi R; Salvador L
Breast Cancer Res Treat; 1989 Mar; 13(2):123-33. PubMed ID: 2730960
[TBL] [Abstract][Full Text] [Related]
6. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
Safi F; Kohler I; Röttinger E; Beger H
Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
[TBL] [Abstract][Full Text] [Related]
7. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse.
Sugano K; Ushiama M; Fukutomi T; Tsuda H; Kitoh T; Ohkura H
Int J Cancer; 2000 Jul; 89(4):329-36. PubMed ID: 10956406
[TBL] [Abstract][Full Text] [Related]
8. Circulating CA 549 and other associated antigens in breast cancer patients.
Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R
Oncology; 1994; 51(1):18-21. PubMed ID: 8265097
[TBL] [Abstract][Full Text] [Related]
9. Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Iaffaioli RV; Caponigro F; Esposito G; Pagliarulo C; Deplacido S; Ungaro B; Bazzicalupo L; Frasci G; Bianco AR
Int J Biol Markers; 1991; 6(1):21-4. PubMed ID: 1856513
[TBL] [Abstract][Full Text] [Related]
10. CEA and CA 15-3 in primary and recurrent breast cancer.
O'Dwyer PJ; Duffy MJ; O'Sullivan F; McDermott E; Losty P; O'Higgins NJ
World J Surg; 1990; 14(5):562-5; discussion 565-6. PubMed ID: 2238654
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of determination of CA-125 in monitoring patients with ovarian carcinoma.
Kamińska JA; Kowalska MM; Sablińska B; Pietrzak P
Eur J Gynaecol Oncol; 1993; 14 Suppl():128-32. PubMed ID: 8200363
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer.
Safi F; Kuhns V; Beger HG
Int J Biol Markers; 1995; 10(2):100-6. PubMed ID: 7561233
[TBL] [Abstract][Full Text] [Related]
13. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma.
Meisel M; Straube W; Weise J; Burkhardt B
Arch Gynecol Obstet; 1995; 256(1):9-15. PubMed ID: 7726659
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of tumour markers CA 19-9 and CA-50 in sera from patients with pancreatic duct carcinoma.
Von Rosen A; Linder S; Harmenberg U; Wiechel KL
Surg Oncol; 1992 Apr; 1(2):109-13. PubMed ID: 1341241
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of CA 15.3 in the post-operative follow-up of breast cancer patients.
Scaramuzzi M; Amorotti C; De Palma M; Falchi AM; Baldini E; De Maria D; Casolo P
Int J Biol Markers; 1990; 5(1):22-6. PubMed ID: 2230348
[TBL] [Abstract][Full Text] [Related]
16. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.
Chan DW; Beveridge RA; Muss H; Fritsche HA; Hortobagyi G; Theriault R; Kiang D; Kennedy BJ; Evelegh M
J Clin Oncol; 1997 Jun; 15(6):2322-8. PubMed ID: 9196146
[TBL] [Abstract][Full Text] [Related]
17. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.
Pectasides D; Mylonakis A; Kostopoulou M; Papadopoulou M; Triantafillis D; Varthalitis J; Dimitriades M; Athanassiou A
Am J Clin Oncol; 1997 Aug; 20(4):348-53. PubMed ID: 9256887
[TBL] [Abstract][Full Text] [Related]
18. Comparison of breast cancer mucin (BCM) and CA 15-3 in human breast cancer.
Garcia MB; Blankenstein MA; van der Wall E; Nortier JW; Schornagel JH; Thijssen JH
Breast Cancer Res Treat; 1990 Dec; 17(2):69-76. PubMed ID: 2096994
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous evaluation of epithelial cell function by CA 125 and stromal cell activity by aminoterminal propeptide of type III procollagen (PIIINP) in ovarian carcinoma.
Tomás C; Penttinen J; Risteli J; Risteli L; Kauppila A
Ann Med; 1990 Apr; 22(2):115-21. PubMed ID: 2361007
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of preoperative serum CA 242 in Esophageal squamous cell carcinoma cases.
Feng JF; Huang Y; Chen QX
Asian Pac J Cancer Prev; 2013; 14(3):1803-6. PubMed ID: 23679277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
